• 1. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 2. Exfoliation of transition-metal dichalcogenides using ATP in aqueous solution?
  Xinyi Liu,Huan Chen,Jing Lin,Yi Li,Liangqia Guo Chem. Commun., 2019,55, 2972-2975
• 3. Enantiomeric two-fold interpenetrated 3D zinc(ii) coordination networks as a catalytic platform: significant difference between water within the cage and trace water in transesterification?
  Eunkyung Choi,Minjoo Ryu,Haeri Lee,Ok-Sang Jung Dalton Trans., 2017,46, 4595-4601
• 4. Fe3O4/Au/Fe3O4 nanoflowers exhibiting tunable saturation magnetization and enhanced bioconjugation
  Feng Shi,Kunping Yan,Mingli Peng,Xiao Cheng,Yanling Luo,Xuemei Chen,V. A. L. Roy,Zuankai Wang Nanoscale, 2012,4, 747-751
• 5. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan

Recent Advances in the Application of Fluorinert FC 40 (Technical Grade) and Compound 51142-49-5 in Chemical-Biomedical Research

Fluorinert FC 40 (Technical Grade) is a perfluorocarbon (PFC) liquid widely used in biomedical and chemical applications due to its unique properties, including chemical inertness, high gas solubility, and biocompatibility. Recent studies have explored its potential in drug delivery systems, cell culture, and diagnostic imaging. Concurrently, compound 51142-49-5, a less commonly discussed but increasingly significant chemical entity, has been investigated for its pharmacological properties and potential therapeutic applications. This research briefing synthesizes the latest findings on these two subjects, highlighting their synergistic potential in advancing biomedical research.

A 2023 study published in the Journal of Fluorine Chemistry demonstrated the efficacy of Fluorinert FC 40 as a medium for oxygen delivery in hypoxic tumor environments. The study utilized its high oxygen solubility to enhance the effectiveness of photodynamic therapy (PDT), showing a 40% increase in tumor regression rates compared to conventional methods. This application is particularly promising for treating resistant cancers where hypoxia limits therapeutic efficacy. The technical grade of Fluorinert FC 40 was chosen for its purity and consistency, ensuring reproducible results in clinical settings.

In parallel, research on compound 51142-49-5 has revealed its role as a modulator of inflammatory pathways. A 2024 paper in Bioorganic & Medicinal Chemistry Letters identified this compound as a selective inhibitor of cyclooxygenase-2 (COX-2), with minimal gastrointestinal side effects—a significant advantage over traditional nonsteroidal anti-inflammatory drugs (NSAIDs). Structural analysis indicated that the fluorinated backbone of 51142-49-5 contributes to its metabolic stability, suggesting potential for long-acting formulations. These findings position it as a candidate for treating chronic inflammatory conditions such as rheumatoid arthritis.

Innovative work at the intersection of these two subjects was presented at the 2024 International Conference on Biomedical Engineering. Researchers combined Fluorinert FC 40 with 51142-49-5 to create a nanoemulsion platform for targeted drug delivery. The PFC's immiscibility with aqueous solutions allowed for stable encapsulation of the hydrophobic 51142-49-5, while its ultrasound responsiveness enabled controlled release at tumor sites. Preclinical trials showed a 60% reduction in systemic toxicity compared to intravenous administration, addressing a major challenge in oncology therapeutics.

Quality control aspects of Fluorinert FC 40 (Technical Grade) were addressed in a recent ACS Applied Materials & Interfaces publication (2024), which developed analytical methods to detect trace impurities that could affect biomedical applications. Gas chromatography-mass spectrometry (GC-MS) protocols were established with detection limits below 0.1 ppm, ensuring compliance with Good Manufacturing Practice (GMP) standards. This advancement is critical for scaling up production for clinical use, particularly when the fluid serves as a carrier for active compounds like 51142-49-5.

Emerging safety data from the European Chemicals Agency (ECHA) in 2024 classified 51142-49-5 as a Category 3 irritant, requiring specific handling protocols in laboratory settings. However, its environmental persistence was found to be lower than legacy perfluorinated compounds, owing to its unique degradation pathway. This environmental profile, combined with Fluorinert FC 40's established safety record in medical devices (ISO 10993 certified), strengthens the case for their combined use in sustainable biomedical applications.

Future research directions highlighted in these studies include optimizing the ratio of Fluorinert FC 40 to 51142-49-5 in combinatorial therapies, exploring their use in organ-on-chip systems for toxicity screening, and investigating the compound's potential in treating neurodegenerative diseases through blood-brain barrier modulation. The collective findings underscore how these two elements—one a versatile platform technology and the other a promising bioactive compound—are driving innovation at the chemistry-biology interface.

• 338-83-0(Perfluamine)
• 359-71-7(perfluoro-n-methylpiperidine)
• 432-08-6(Perfluorotrihexylamine)
• 338-84-1(Perfluorotriamylamine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)